Results of the Latin American Bone Marrow Transplantation Society (LABMT) activity survey 2019-2022: the impact of the COVID-19 pandemic and the increase in related haploidentical donors - Scorecard - MDSpire

Results of the Latin American Bone Marrow Transplantation Society (LABMT) activity survey 2019-2022: the impact of the COVID-19 pandemic and the increase in related haploidentical donors

  • By

  • Sebastian Galeano

  • Carmem Bonfim

  • Amado Karduss

  • Gregorio Jaimovich

  • Andrés Gómez-De León

  • Gustavo Bettarello

  • Anderson Simione

  • Cinthya Correa

  • Helen Baldomero

  • Daniel Neumann

  • Ana Lisa Basquiera

  • Mariano Berro

  • Guillermina Remaggi

  • Ariel Amaru

  • Fernando Barroso

  • Adriana Seber

  • Francisco Barriga

  • Julia Palma

  • Bárbara Puga

  • Matías Sánchez

  • Juan Manuel Herrera

  • Calixto Hernández

  • David Gómez-Almaguer

  • Félix Gaytán Morales

  • Guillermo J. Ruiz-Argüelles

  • Ninotzka Mendoza

  • María Liz Benítez

  • Alfredo Wong

  • Carolina Pagés

  • Marcos Hernández

  • Dietger Niederwieser

  • Damiano Rondelli

  • Cristóbal Frutos

  • April 18, 2025

  • 0 min

Share

Clinical Scorecard: Findings from the 2019-2022 Activity Survey of the Latin American Bone Marrow Transplantation Society: Effects of the COVID-19 Pandemic and the Rise in Haploidentical Donors

At a Glance

CategoryDetail
ConditionHematological diseases, solid tumors, bone marrow failure syndromes, hemoglobinopathies, inborn errors of metabolism and immunity requiring hematopoietic stem cell transplantation (HCT)
Key MechanismsHematopoietic stem cell transplantation using autologous or allogeneic grafts from matched related, unrelated, or haploidentical donors; stem cell sources include bone marrow, peripheral blood stem cells, and cord blood
Target PopulationAdult (≥18 years) and pediatric (<18 years) patients in Latin America undergoing first HCT
Care SettingTransplant centers across 15 Latin American countries participating in the Latin American Bone and Marrow Transplantation Society (LABMT) registry

Key Highlights

  • From 2019 to 2022, 6767 first HCTs were reported in Latin America with 39% allogeneic and 61% autologous transplants.
  • Pediatric HCTs comprised 1121 cases with 82% allogeneic and 18% autologous; adult HCTs were predominantly autologous (69%).
  • Haploidentical donors (familial HLA non-identical) represent the majority of non-identical family donor transplants, reflecting a rise in their use.

Guideline-Based Recommendations

Diagnosis

  • Classify patients by age (adult ≥18 years, pediatric <18 years) and underlying disease according to EBMT disease classifications.
  • Use donor typing to distinguish familial HLA identical matched related donors and familial HLA non-identical donors (mostly haploidentical).

Management

  • Select stem cell source based on clinical indication: bone marrow, peripheral blood stem cells, or cord blood.
  • Consider haploidentical donors as a major donor source when matched related or unrelated donors are unavailable.

Monitoring & Follow-up

  • Collect and report first HCT data annually to registries such as LABMT and WBMT for activity monitoring and quality improvement.
  • Monitor transplant rates per 10 million population to assess access and trends regionally.

Risks

  • Recognize potential increased risks associated with haploidentical transplants compared to matched donors, requiring appropriate clinical management.
  • Account for socio-economic and healthcare system factors influencing transplant access and outcomes.

Patient & Prescribing Data

First hematopoietic stem cell transplant recipients in Latin America, both pediatric and adult populations

Autologous transplants predominate in adults, while allogeneic transplants are more frequent in pediatric patients; haploidentical donors are increasingly utilized among allogeneic transplants.

Clinical Best Practices

  • Ensure comprehensive data collection through national and regional transplant registries to track HCT activity and outcomes.
  • Promote the use of haploidentical donors to expand donor availability in Latin America.
  • Stratify transplant indications and donor selection by patient age and disease status to optimize outcomes.

References

Original Source(s)

Results of the Latin American Bone Marrow Transplantation Society (LABMT) activity survey 2019-2022: the impact of the COVID-19 pandemic and the increase in related haploidentical donors

  • by Sebastian Galeano, Carmem Bonfim, Amado Karduss, Gregorio Jaimovich, Andrés Gómez-De León, Gustavo Bettarello, Anderson Simione, Cinthya Correa, Helen Baldomero, Daniel Neumann, Ana Lisa Basquiera, Mariano Berro, Guillermina Remaggi, Ariel Amaru, Fernando Barroso, Adriana Seber, Francisco Barriga, Julia Palma, Bárbara Puga, Matías Sánchez, Juan Manuel Herrera, Calixto Hernández, David Gómez-Almaguer, Félix Gaytán Morales, Guillermo J. Ruiz-Argüelles, Ninotzka Mendoza, María Liz Benítez, Alfredo Wong, Carolina Pagés, Marcos Hernández, Dietger Niederwieser, Damiano Rondelli, Cristóbal Frutos

  • April 18, 2025

Related Content

Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

Rare COVID Vaccine Clotting Linked to Adenoviral Protein 

Antibody proteomics and immunogenetics identify adenoviral protein VII as the trigger of PF4-targeting antibodies 

  • April 21, 2026

  • 2 min
COVID-19-Associated Mucormycosis: Identifying Mortality Predictors in a Retrospective Cohort Study